This meta-analysis included individual participant data from 22 trials of statin versus control (n=134 537; mean LDL cholesterol diff erence 1·08 mmol/L; median follow-up 4·8 years) and fi ve trials of more versus less statin (n=39 612; diff erence 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal myocardial infarction or coronary death), strokes, or coronary revascularisations. Participants were separated into fi ve categories of baseline 5-year major vascular event risk on control therapy (no statin or low-intensity statin) (